GALERA THERAPEUTICS INC (GRTX)

US36338D1081 - Common Stock

0.1782  0 (-2.46%)

After market: 0.1824 +0 (+2.36%)

GALERA THERAPEUTICS INC

NASDAQ:GRTX (9/27/2023, 7:00:01 PM)

After market: 0.1824 +0 (+2.36%)

0.1782

0 (-2.46%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-14 2023-08-14/bmo
Earnings (Next)11-07 2023-11-07/bmo
Ins Owners1.05%
Inst Owners42.27%
Market Cap7.83M
Shares43.93M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts47.5
IPO11-07 2019-11-07
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

GRTX Daily chart

Company Profile

Galera Therapeutics, Inc. is a clinical stage biotechnology company, which engages in developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. The company is headquartered in Malvern, Pennsylvania and currently employs 31 full-time employees. The company went IPO on 2019-11-07. The firm is focused on developing and commercializing a pipeline of therapeutic candidates to transform radiotherapy in cancer. Its lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic in development for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC) and for the reduction of esophagitis in patients with lung cancer. The company has completed Phase III Reduction in Oral Mucositis with Avasopasem Manganese (ROMAN) trial of GC4419 for the reduction of radiotherapy-induced SOM in patients with locally advanced HNC. Its second dismutase mimetic product candidate, rucosopasem manganese (GC4711), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).

Company Info

GALERA THERAPEUTICS INC

45 Liberty Blvd., Suite 230

Malvern PENNSYLVANIA 19355

P: 16107251500.0

CEO: J. Mel Sorensen

Employees: 31

Website: https://www.galeratx.com/

GRTX News

News Image2 days ago - ChartmillCurious about the stocks that are showing activity after the closing bell on Monday?

As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

News Image9 days ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Pre-market stock movers are a hot topic on Tuesday as investors seek out the latest news on the biggest traders this morning!

News Image10 days ago - Galera TherapeuticsGalera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem
News Image10 days ago - Galera TherapeuticsGalera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem

MALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on...

News Image23 days ago - Galera TherapeuticsGalera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
News Imagea month ago - Galera TherapeuticsGalera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates

GRTX Twits

Here you can normally see the latest stock twits on GRTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example